ES2209217T3 - Formulacion anestesica. - Google Patents
Formulacion anestesica.Info
- Publication number
- ES2209217T3 ES2209217T3 ES98954639T ES98954639T ES2209217T3 ES 2209217 T3 ES2209217 T3 ES 2209217T3 ES 98954639 T ES98954639 T ES 98954639T ES 98954639 T ES98954639 T ES 98954639T ES 2209217 T3 ES2209217 T3 ES 2209217T3
- Authority
- ES
- Spain
- Prior art keywords
- saccharide
- solution according
- anesthetic agent
- bupivacaine
- previous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 230000003444 anaesthetic effect Effects 0.000 title claims description 5
- 238000009472 formulation Methods 0.000 title description 16
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 3
- 239000003193 general anesthetic agent Substances 0.000 claims abstract 9
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 19
- 229960003150 bupivacaine Drugs 0.000 claims description 17
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 16
- 229960004288 levobupivacaine Drugs 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 150000003839 salts Chemical group 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 6
- -1 2,6-dimethylphenyl Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001767 cationic compounds Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229910001411 inorganic cation Inorganic materials 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 239000008121 dextrose Substances 0.000 description 11
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001949 anaesthesia Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- LEBVLXFERQHONN-MRXNPFEDSA-N dextrobupivacaine Chemical compound CCCCN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-MRXNPFEDSA-N 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002693 spinal anesthesia Methods 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229940127245 spinal anesthetics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9724506 | 1997-11-19 | ||
| GBGB9724506.2A GB9724506D0 (en) | 1997-11-19 | 1997-11-19 | Levobupivacaine and its use |
| GBGB9818109.2A GB9818109D0 (en) | 1998-08-19 | 1998-08-19 | Anaesthetic Formulation |
| GB9818109 | 1998-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2209217T3 true ES2209217T3 (es) | 2004-06-16 |
Family
ID=26312628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98954639T Expired - Lifetime ES2209217T3 (es) | 1997-11-19 | 1998-11-19 | Formulacion anestesica. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5932597A (enExample) |
| EP (1) | EP1032390B1 (enExample) |
| JP (1) | JP2001522888A (enExample) |
| KR (1) | KR100695588B1 (enExample) |
| CN (1) | CN1131033C (enExample) |
| AT (1) | ATE253913T1 (enExample) |
| AU (1) | AU740914B2 (enExample) |
| BR (1) | BR9814883A (enExample) |
| CA (1) | CA2308495C (enExample) |
| DE (1) | DE69819770T2 (enExample) |
| DK (1) | DK1032390T3 (enExample) |
| ES (1) | ES2209217T3 (enExample) |
| HU (1) | HU228143B1 (enExample) |
| IL (1) | IL135922A0 (enExample) |
| NO (1) | NO328684B1 (enExample) |
| PT (1) | PT1032390E (enExample) |
| WO (1) | WO1999025349A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824161D0 (en) * | 1998-11-04 | 1998-12-30 | Darwin Discovery Ltd | Drug formulation |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| HUE026034T2 (en) | 2002-12-13 | 2016-05-30 | Durect Corp | Oral delivery system containing an oral high-viscosity carrier |
| LT2767292T (lt) | 2004-09-17 | 2016-12-12 | Durect Corporation | Palaikomosios vietinės anestezijos mišinys su saib |
| US20060270708A1 (en) * | 2005-05-25 | 2006-11-30 | Navinta Llc | Novel process for preparation of isotonic aqueous injection of ropivacaine |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| EP2117521B1 (en) | 2006-11-03 | 2012-06-27 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
| JP2011506318A (ja) * | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | 経口医薬製剤 |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| CN105612155A (zh) * | 2012-05-10 | 2016-05-25 | 塞利克斯比奥私人有限公司 | 治疗局部疼痛的组合物和方法 |
| TW201521769A (zh) | 2013-03-15 | 2015-06-16 | Durect Corp | 具有流變改質劑以減少溶解變異性之組成物 |
| EP3331508B1 (en) * | 2015-07-13 | 2024-08-14 | Neon Laboratories Ltd. | Hyperbaric solution injection of levobupivacaine hydrochloride comprising levobupivacaine hydrochloride |
| US12274794B2 (en) | 2016-07-06 | 2025-04-15 | Orient Pharma Co., Ltd. | Oral dosage form with drug composition, barrier layer and drug layer |
| CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| EP4277702A1 (en) | 2021-01-12 | 2023-11-22 | Durect Corporation | Sustained release drug delivery systems and related methods |
| WO2025175174A1 (en) * | 2024-02-14 | 2025-08-21 | The Children's Medical Center Corporation | 2'-6'-pipecoloxylidide as a sensory-selective anesthetic |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8802564D0 (sv) * | 1988-07-08 | 1988-07-08 | Astra Ab | New synergistic preparations and a new method of alleviation of pain |
| ATE210982T1 (de) * | 1993-10-13 | 2002-01-15 | Darwin Discovery Ltd | Analgetisches mittel und dessen verwendung |
| GB9321061D0 (en) * | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
-
1998
- 1998-11-19 ES ES98954639T patent/ES2209217T3/es not_active Expired - Lifetime
- 1998-11-19 HU HU0004665A patent/HU228143B1/hu unknown
- 1998-11-19 CA CA002308495A patent/CA2308495C/en not_active Expired - Lifetime
- 1998-11-19 WO PCT/GB1998/003479 patent/WO1999025349A1/en not_active Ceased
- 1998-11-19 PT PT98954639T patent/PT1032390E/pt unknown
- 1998-11-19 KR KR1020007005443A patent/KR100695588B1/ko not_active Expired - Lifetime
- 1998-11-19 AT AT98954639T patent/ATE253913T1/de active
- 1998-11-19 DE DE69819770T patent/DE69819770T2/de not_active Expired - Lifetime
- 1998-11-19 DK DK98954639T patent/DK1032390T3/da active
- 1998-11-19 JP JP2000520782A patent/JP2001522888A/ja active Pending
- 1998-11-19 AU AU11684/99A patent/AU740914B2/en not_active Expired
- 1998-11-19 BR BR9814883-4A patent/BR9814883A/pt not_active Application Discontinuation
- 1998-11-19 CN CN98811339A patent/CN1131033C/zh not_active Expired - Lifetime
- 1998-11-19 US US09/195,908 patent/US5932597A/en not_active Expired - Lifetime
- 1998-11-19 IL IL13592298A patent/IL135922A0/xx not_active IP Right Cessation
- 1998-11-19 EP EP98954639A patent/EP1032390B1/en not_active Expired - Lifetime
-
2000
- 2000-05-18 NO NO20002545A patent/NO328684B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE253913T1 (de) | 2003-11-15 |
| HK1026848A1 (en) | 2000-12-29 |
| DE69819770D1 (de) | 2003-12-18 |
| WO1999025349A1 (en) | 1999-05-27 |
| HUP0004665A3 (en) | 2004-05-28 |
| HUP0004665A2 (hu) | 2001-04-28 |
| KR100695588B1 (ko) | 2007-03-14 |
| HU228143B1 (en) | 2012-12-28 |
| CN1279607A (zh) | 2001-01-10 |
| BR9814883A (pt) | 2000-10-03 |
| CN1131033C (zh) | 2003-12-17 |
| CA2308495C (en) | 2009-01-06 |
| CA2308495A1 (en) | 1999-05-27 |
| KR20010032241A (ko) | 2001-04-16 |
| EP1032390B1 (en) | 2003-11-12 |
| DE69819770T2 (de) | 2004-09-23 |
| EP1032390A1 (en) | 2000-09-06 |
| NO328684B1 (no) | 2010-04-26 |
| AU740914B2 (en) | 2001-11-15 |
| AU1168499A (en) | 1999-06-07 |
| IL135922A0 (en) | 2001-05-20 |
| JP2001522888A (ja) | 2001-11-20 |
| NO20002545D0 (no) | 2000-05-18 |
| PT1032390E (pt) | 2004-04-30 |
| DK1032390T3 (da) | 2004-03-15 |
| US5932597A (en) | 1999-08-03 |
| NO20002545L (no) | 2000-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2209217T3 (es) | Formulacion anestesica. | |
| ES2223549T3 (es) | Formulacion que contiene moxifloxacino y sal comun. | |
| ES2253469T3 (es) | Emulsiones grasas parenterales que comprenden edetato como conservante. | |
| ES2198127T3 (es) | Composiciones farmaceuticas autoclaveables que contienen un agente quelante. | |
| US11389416B2 (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| EP0546160B1 (en) | Method of reversing local anesthesia and reagent system therefor | |
| NZ208127A (en) | Pharmaceutical compositions containing ranitidine | |
| AU1165292A (en) | Compositions | |
| ES2236180T3 (es) | Composiciones oftalmicas antialergicas adecuadas para uso con lentes de contacto. | |
| ES2259313T3 (es) | Inyeccion de famotidina. | |
| ES2220516T3 (es) | Formulacion medicamentosa acuosa de moxifloxacino o sales del mismo. | |
| ES2201179T3 (es) | Levobupivacaina y su utilizacion coo analgesico en mujeres embarazadas. | |
| ES2277397T3 (es) | Formas liquidas de administracion de productos farmaceuticos que contienen oxazafosforina. | |
| ES2215856T3 (es) | Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion. | |
| MXPA00004746A (en) | Anaesthetic formulation | |
| HK1026848B (en) | Anaesthetic formulation | |
| ES2331266T3 (es) | Nueva composicion hiperbarica estable que comprende hcl de prilocina, uso de dicha nueva composicion para anestesia intratecal y metodo para la fabricacion de dicha composicion. | |
| ES2441790T3 (es) | Nuevo uso para una composición que comprende HCl de cloroprocaína, una nueva composición que comprende HCl de cloroprocaína y un procedimiento para su fabricación | |
| JPS62265220A (ja) | １，４−ジヒドロキシ−５，８−ビス〔２−（２−ヒドロキシエチルアミノ）−エチルアミノ〕アントラキノン二塩酸塩の安定な注射用医薬配合物 | |
| JP2004269363A (ja) | アセトアミノフェンを含有する安定な水性医薬組成物 | |
| JPH10306040A (ja) | 局所麻酔用組成物 | |
| BRPI0707788B1 (pt) | Composição hiperbárica estável, compreendendo cloridrato de prilocaína, uso da dita nova composição para anestesia intratecal e método de fabricação da dita composição | |
| IT9021913A1 (it) | Composizioni farmaceutiche per la somministrazione per via nasale a base di calcitonina |